Company Introduction

“Breakthroughs for the Ideal Medicine You Desire”
Golden Biotechnology Corporation is a clinical stage biopharmaceutical company focused on discovery and clinical development of innovative therapeutic new drugs (NCE), and dedicated to improving quality of life by developing products that prevent and treat diseases.

Brief description of main products or services 

GoldenBiotech discovered from its own screening platforms Antroquinonol^® (trade name HOCENA^® ), which has been granted more than 150 patents worldwide for its structure, preparation and applications in oncology, cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases and infectious diseases. Since 2013, Antroquinonol® was authorized Phase II clinical trial on NSCLC by US FDA and Taiwan FDA and trial completed in 2019. The clinical trials on acute myeloid leukemia (AML) has also completed in 2020, and the multi-national trials on pancreatic cancer and COVID-19 expected to accomplish in mid-2021. Orphan Drug Designations (ODD) were obtained in treatment of pancreatic cancer (US #14-4608 & EU), AML (US#15-4763) and hepatocellular carcinoma (US#15-4881).
 
Antroquinonol^® exhibits a broad spectrum of activities against malignancies in-vivo and in-vitro, and offers a better solution than the single-action compounds the industry developed so far. Antroquinonol’s multiple, simultaneous, and synergistic actions enable positive outcomes. Antroquinonol^® can be used as a monotherapy, combination- or adjuvant-therapy to complement other drugs, or as a best supportive care. Demonstrated safety profile and efficacy make Antroquinonol^® an ideal asset in treating diseases and improving overall quality of life of patients.
 
GoldenBiotech is seeking for out-licensing and/or co-development opportunities to further clinical ,development and commercialization.